Enclomiphene Citrate Monitoring for Older Adults (Ages 50 to 64): A Complete Clinical Guide

Is there a monitoring schedule for adults 50 to 64?

There is no approved one. Enclomiphene has no FDA-approved product and no approved dose [1], and in January 2018 the EMA's CHMP adopted a negative opinion recommending refusal of EnCyzix, based on four main studies in 588 patients [2].

A 2026 British Society of Sexual Medicine position statement says the manufacturer discontinued development in 2021 and advises use only by experienced clinicians in specialist or research settings, because long-term efficacy and safety data are lacking [6].

What the phase 3 trials measured, and when

The 12-week ZA-301 and ZA-302 trials enrolled men with low morning testosterone and normal sperm concentration [3][8]. The later pair compared enclomiphene with AndroGel 1.62% for 16 weeks in overweight men aged 18 to 60 with morning testosterone at or below 300 ng/dL [5]. The endpoints of these trials were testosterone, LH, FSH and semen parameters, not symptoms or quality of life [3][5].

The phase 3 protocols used 12.5 mg once daily, with up-titration to 25 mg at week 6 if morning testosterone stayed below 300 ng/dL [3]. The week-6 testosterone check is the monitoring step written into the phase 3 protocols.

Testosterone, LH and FSH: what the trials found

• In ZA-301, 78.8% (95% CI 70.3 to 85.3, n=113) of patients pooled across enclomiphene arms reached an average 24-hour testosterone within the normal range of 300 to 1040 ng/dL at 12 weeks [3].
• In ZA-302 the figure was 81.3% (95% CI 73.9 to 87.0, n=134) [8].
• In the 16-week comparison, total testosterone rose in every treatment group, while LH and FSH rose with enclomiphene and fell with testosterone gel [5].
• A meta-analysis of randomized SERM trials (clomiphene and enclomiphene combined) put total testosterone 273.76 ng/dL above placebo (95% CI 191.87 to 355.66), with high heterogeneity (I2 89%), and found no significant difference from testosterone gel [9].

FDA said it was unclear whether raising testosterone produced clinical benefit, and EMA noted that the studies did not examine whether symptoms such as bone strength, weight gain, impotence or libido improved [1][2].

Estradiol, PSA and hematocrit

FDA's 2022 summary of published trials, adverse event reports and EMA's review lists raised estradiol, raised PSA and raised hematocrit among the safety concerns, alongside cardiac and thromboembolic events and the absence of long-term safety data [1].

Estradiol moved differently on enclomiphene than on the clomiphene mixture in one study. In a retrospective single-centre series of 66 men who took clomiphene and later enclomiphene, estradiol changed by -5.92 pg/mL on enclomiphene versus +17.50 pg/mL on clomiphene (P=0.001), and adverse effects were less frequent (odds ratio 0.18, 95% CI 0.07 to 0.44) [10]. That is a retrospective comparison, not a randomized trial.

Eyes and vision

EMA asked for ocular monitoring, and cataracts were seen in nonclinical studies but were not conclusively linked to people [1]. In the enclomiphene trials, blurred vision was among the reasons patients stopped treatment [8].

The Clomid label covers clomiphene citrate — the mixture, not enclomiphene. It reports visual symptoms such as blurring, spots or flashes in 1.5% of 8,029 patients in clinical studies and reports that prolonged or possibly irreversible visual disturbances have occurred. These label findings apply to clomiphene citrate, not enclomiphene [11].

Enclomiphene is not clomiphene

Clomiphene citrate is a mixture of enclomiphene (trans) and zuclomiphene (cis); per FDA, the USP monograph gives enclomiphene content of clomiphene as 50 to 70 percent [1]. Clomid's only approved use is ovulatory dysfunction in women desiring pregnancy, and its label states there are no adequate or well-controlled studies demonstrating effectiveness in male infertility [11]. The label's contraindications — liver disease, uncontrolled thyroid or adrenal dysfunction, pituitary tumour and pregnancy — and its warnings apply to the mixture and are not established for enclomiphene alone [11].

The pharmacokinetics differ too. Zuclomiphene has a longer half-life and was still detectable more than a month after a single dose in normal volunteers, whereas enclomiphene peaks 2 to 3 hours after a dose, has a half-life of about 10 hours, is metabolized mainly to 4-hydroxy enclomiphene and is excreted mainly in faeces [1][11].

Sperm counts

Sperm concentration fell by 50% or more in 14.2% of enclomiphene-treated men versus 2.6% on placebo in ZA-301 [3], and in 14.2% versus 4.3% in ZA-302 [8]. In the 16-week comparison with AndroGel 1.62%, sperm concentration stayed in the normal range on enclomiphene while there was a marked reduction in spermatogenesis on testosterone gel [5]. In a 12-man phase 2b study, sperm counts rose in 7 of 7 men on enclomiphene at 3 months, and testosterone returned to pre-treatment values one month after stopping [12].

Cardiovascular questions in the 50-to-64 range

FDA's 2022 list includes cardiac and thromboembolic events, including pulmonary embolism and deep vein thrombosis in a safety study [1]. EMA noted a slightly higher rate of cardiac and thromboembolic events than with testosterone, and venous thromboembolism was one of its stated reasons for refusing authorisation [1][2].

TRAVERSE is a cardiovascular outcome trial of testosterone gel, not enclomiphene. It randomized 5,246 men aged 45 to 80 with existing or high cardiovascular risk to 1.62% testosterone gel or placebo; the primary composite endpoint was noninferior (hazard ratio 0.96, 95% CI 0.78 to 1.17), with more atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group [13]. FDA reported cardiac and blood-clot events in enclomiphene safety data, but the testosterone-gel cardiovascular trial cannot establish enclomiphene's cardiovascular risk [1][13].

Side effects seen in the trials

The most frequent were headache, hot flushes, nausea and muscle spasm, and reasons for stopping included blurred vision, muscle spasm, headache and aggression [8]. In ZA-302, headache was reported by 7 of 112 men on 12.5 mg versus 1 of 47 on placebo, and nausea by 4 of 112 versus 3 of 47 [8].

Regulatory and compounding status

Enclomiphene is not FDA-approved [1]. FDA's bulk drug substance list, updated 14 May 2026, places enclomiphene citrate in Category 1, bulk drug substances under evaluation — an enforcement-discretion position, not an approval and not a finding of safety or effectiveness [7]. At the June 2022 Pharmacy Compounding Advisory Committee, FDA proposed not adding it to the allowed list and the committee voted 4 yes, 8 no [14]. It does not appear on FDA's list of bulk substances that present significant safety risks, and compounded enclomiphene has not been reviewed by FDA for safety, effectiveness or quality [15].

HealthRX.com offers enclomiphene by prescription.